Oruka Therapeutics News and Activities
Presence
Oruka Therapeutics is a biotechnology company that develops medicines for chronic skin diseases. Its main products and services include antibody therapies and drug research for patients, doctors, and healthcare providers.
Oruka Therapeutics products and services overview:
- Antibody therapies
- Skin disease treatments
- Drug research
- Clinical development
Revenue: ~$0 million
Employees: 60
Headquarters: Menlo Park, United States (USA)
Acquisition, funding and merger involving Paragon Therapeutics.
- Oruka Therapeutics has just announced a $700 Million fundraising (posted on April 29 2026).
- Oruka Therapeutics has just announced a $180 Million fundraising (posted on September 18 2025).
- Arca Biopharma and Oruka Therapeutics have announced they will merge (posted on September 7 2024)..
Executives
View the org chart displaying its 30 main executives
Most searched biographies at Oruka Therapeutics
- Lawrence Klein, Chief Executive Officer and Director
- Chris Martin, Director
- Samarth Kulkarni, Director
Popular executive movements at Oruka Therapeutics
- Cameron Turtle, Director, has left the company (posted on December 12 2025).
- Chris Martin has joined the company as Director (posted on December 12 2025).
Create your alert
to follow the executive moves at Oruka Therapeutics.
Biotechnology
Paragon Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Oruka Therapeutics
- Oruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference | Thu, 05/28/2026 - 08:00
- Oruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Wed, 05/13/2026 - 16:04
- Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology | Wed, 05/06/2026 - 08:05
- Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering | Tue, 04/28/2026 - 19:43
- Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering | Mon, 04/27/2026 - 16:17
- Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Thu, 03/12/2026 - 16:06
- Oruka Therapeutics to Participate in Multiple Upcoming Conferences | Mon, 02/09/2026 - 07:00
- Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 | Mon, 01/12/2026 - 07:00
- Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference | Tue, 01/06/2026 - 07:00
- Oruka Therapeutics Announces New Board Member and Board Transition | Thu, 12/11/2025 - 16:01
- View more press releases Close
Social media about Oruka Therapeutics
- Oruka Therapeutics on Wikipedia, Google News & Yahoo Finance
- Oruka Therapeutics on LinkedIn, X (Twitter) & YouTube
